How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?  Pieter Sonneveld,

Slides:



Advertisements
Similar presentations
Relapsed and Refractory Myeloma
Advertisements

Palumbo A et al. Proc ASH 2012;Abstract 446.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Relapsed and Refractory Myeloma Case 2
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Multiple Myeloma Update from the American Society of Clinical Oncology (ASCO) 43 rd Annual Meeting Welcome and Introduction Nikhil Munshi, MD Dana-Farber.
Relapsed and Refractory Myeloma Case 1 James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.
Update on Diagnosis and Treatments of Multiple Myeloma Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.
Sagar Lonial, MD Professor and Chair Hematology and Medical Oncology
Relapsed / Refractory Multiple Myeloma
Myeloma hope new treatment in the horizon
Nicoletta Colombo, Martin Gore 
MRA Clinical Trials Day Myeloma UK Clinical Trial Network
A Phase I/II Trial of Bendamustine and Pomalidomide with Dexamethasone (BPd) in Patients with Relapsed/Refractory Multiple Myeloma Duke University Cristina.
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
December 7-10, 2013 New Orleans, Louisiana
Abhimanyu Ghose, Ria Kundu, Tahir Latif 
Phase II Study: Pembrolizumab Plus Pomalidomide and Dexamethasone Active in R/R Multiple Myeloma New Findings in Hematology: Independent Conference Coverage.
Mateos MV et al. Proc ASH 2013;Abstract 403.
P. Therasse, S. Carbonnelle, J. Bogaerts 
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Andrzej Jakubowiak  Seminars in Hematology 
Volume 17, Issue 2, Pages (March 2014)
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Future Strategies for Myeloma
Magic Iceland.
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders  Mai F. Tolba, Hany A.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
Meletios A. Dimopoulos, MD
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Challenging Cases in Multiple Myeloma Panel Discussion
James R. Berenson, MD Medical & Scientific Director
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis  Meletios Athanasios.
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( )  Sundar Jagannath, Rafat Abonour, Brian.
Multiple Myeloma: Diagnosis and Treatment
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Multiple Myeloma:2013 Update Genomies
Therapy for Relapsed Multiple Myeloma
The Nurse View: Best Practices in Multiple Myeloma
Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature.
Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.
New Classes of Therapy in Multiple Myeloma
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries  Roberto José Pessoa.
Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.
Therapy for Relapsed Multiple Myeloma
Proteasome Inhibitors and Patients
On the Cusp: New Approaches for Multiple Myeloma
Diagnosis of Multiple Myeloma
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients by Cirino Botta, Domenico Ciliberto,
Treatment options for relapsed and refractory multiple myeloma
Maintenance therapies in Multiple Myeloma
Presentation transcript:

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?  Pieter Sonneveld, Edwin De Wit, Philippe Moreau  Critical Reviews in Oncology / Hematology  Volume 112, Pages 153-170 (April 2017) DOI: 10.1016/j.critrevonc.2017.02.007 Copyright © 2017 Amgen Inc. Terms and Conditions

Fig. 1 Evolving treatment strategies for patients with relapsed and/or refractory multiple myeloma. Figure shows the publication of key clinical trials and European approval of agents for the treatment of relapsed and/or refractory multiple myeloma. aApproved for use only as first-line therapy for multiple myeloma. BCL-2i, B-cell lymphoma 2 inhibitor, BEND, bendamustine; BORT, bortezomib; CARF, carfilzomib; CDKi, cyclin-dependent kinase inhibitor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; HDAC, histone deacetylase; ISA, isatuximab; IXA, ixazomib; KSP-i, kinesin spindle protein inhibitor; LEN, lenalidomide; MARI, marizomib; OPRO, oprozomib; PAN, panobinostat; PD-1, programmed death protein 1; PD-L1, programmed death ligand 1; PIMKi, Pim kinase inhibitor; POM, pomalidomide; RICO, ricolinostat; ROM, romidepsin; SINE, selective inhibitor of nuclear export; THAL, thalidomide; VOR, vorinostat. Critical Reviews in Oncology / Hematology 2017 112, 153-170DOI: (10.1016/j.critrevonc.2017.02.007) Copyright © 2017 Amgen Inc. Terms and Conditions

Fig. 2 Overall response rates in key phase 3 studies in patients with relapsed and/or refractory multiple myeloma. —Approved for use in the USA and in Europe in patients with relapsed and/or refractory multiple myeloma. - - - Approved for use in the USA in patients with relapsed and/or refractory multiple myeloma. aCR not available (ORR: sCR+CR+VGPR+PR); bCR+near CR; cNot yet approved for use in patients with RRMM; dsCR+CR. BORT, bortezomib; CARF, carfilzomib; CR, complete response; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; IMiD, immunomodulatory drug; LEN, lenalidomide; ORR, overall response rate; PAN, panobinostat; PI, proteasome inhibitor; PLD, pegylated liposomal doxorubicin; POM, pomalidomide; PR, partial response; sCR, stringent complete response; THAL, thalidomide; VGPR, very good partial response; VOR, vorinostat. Critical Reviews in Oncology / Hematology 2017 112, 153-170DOI: (10.1016/j.critrevonc.2017.02.007) Copyright © 2017 Amgen Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.